WALDENSTROM MACROGLOBULINEMIA

This study tests a new drug, acalabrutinib, added to standard chemotherapy for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. 63 participants will receive the combination for about a year to see if it improves response rates. The goal is to control th…

This study tests a new drug called sonrotoclax, either alone or with another drug (zanubrutinib), in people with Waldenström macroglobulinemia, a slow-growing blood cancer. The goal is to see if the treatment can shrink tumors and control the disease. About 114 adults with either…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have returned or not responded to prior treatments. The drug delivers radiation directly to cancer cells. A…

This study tests whether adding acalabrutinib to standard rituximab therapy is safe and effective for people with nerve damage (neuropathy) linked to two blood conditions: IgM MGUS or Waldenstrom macroglobulinemia. The 12 participants receive both drugs to see if the combination …

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing types of B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with various subtypes, including follicular lymphoma and chro…

This study tests a chemotherapy-free combination of three drugs (bortezomib, rituximab, ibrutinib) in 53 people with newly diagnosed Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this approach can control the disease for at least one year with fewer …

This early-stage trial tests a new drug (PCI-32765) combined with two standard treatments (rituximab and bendamustine) in 48 adults with relapsed non-Hodgkin lymphoma. The goal is to find the safest dose and see how well the combination works. Participants have specific types of …

This study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find the safest dose and to see if the drug can shri…

This study tests whether adding a drug called cyclophosphamide after a stem cell transplant can lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers or sever…

This early-phase study tests an experimental therapy called NKX019, made from donor immune cells (natural killer cells) engineered to target and kill cancer cells. It is for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to othe…

This study looks at people and families who may have a higher chance of getting blood cancers like leukemia or lymphoma. Researchers want to learn what genes or environmental factors might cause these cancers. Participants fill out health surveys and give blood or cheek cell samp…